Comparing Antibody-Drug Conjugates for Metastatic Breast Cancer
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
Progress Against Cancer
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
Seven immune checkpoint inhibitors, targeting the PD-1, PD-L1, or CTLA-4 proteins, are currently approved for the treatment of cancer....
Metastatic cancer patients nearing death continue to receive high-dose radiation despite guidelines advising against it, and new standards are...
Each year in the United States, about 14,480 women are diagnosed with cervical cancer, and about 4,290 women die of...
Women with breast cancer who choose fertility preservation have treatment outcomes similar to women who don’t undergo fertility preservation.
Researchers aim to minimize disease relapses by targeting multiple proteins.
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented...
Patient expenses for cancer care exceed $21 billion in 2019, the FDA introduces stringent requirements for breast implants and...
Among the studies published during the month of October in the nine AACR journals, the editors have chosen to highlight results from two clinical trials of DNA...
Liver cancer is the second most common cause of cancer-related deaths worldwide. In 2021, it is estimated that more...